Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open-market sales of 30,000 shares of Class A common stock on June 22, 2026. The sales occurred in multiple trades at weighted average prices around $33–$36 per share, as detailed by price ranges in the filing.
The transactions were made under Saxonov’s pre-arranged Rule 10b5-1 trading plan, adopted on November 29, 2025. After these sales, he holds approximately 1,129,853 shares directly, plus additional indirect holdings through the Andromeda Trust, the Y/S Descendants’ Trust, and the Y/S Pot Trust.
10x Genomics, Inc. director Shehnaaz Suliman reported selling a total of 5,723 shares of Class A Common Stock in open-market transactions. The sales occurred on June 16, 2026 at weighted average prices of $32.5890 and $33.2738 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026.
TXG submitted a Form 144 notice listing proposed sales of Class A Common stock tied to multiple RSU vesting events. The filing itemizes vesting dates and per-date share counts such as 156, 530, 466, and 1,113 linked to specific dates between 08/21/2021 and 08/21/2024.
The header shows an intermediary (JP Morgan Securities LLC), a numeric line including 5723, 184395.06, and 116,877,317 with an associated date 06/16/2026. The excerpt focuses on scheduled RSU vesting entries and identifies the securities as Class A Common on Nasdaq.
Teichmann Sarah A. reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Sarah A. Teichmann received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The award was granted at no cash cost per share and increased her direct holdings to 35,609 shares.
Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider through each vesting date.
SULIMAN SHEHNAAZ reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Shehnaaz Suliman received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The grant has no cash purchase price and increases her direct holdings to 37,445 shares. The RSUs vest in four equal quarterly installments starting on May 21, 2026, as long as she continues as a service provider.
STUELPNAGEL JOHN R reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. director John R. Stuelpnagel received an equity award of 8,829 restricted stock units (RSUs), each representing one future share of Class A Common Stock upon vesting. The RSUs vest in four equal installments on each quarterly anniversary of May 21, 2026, as long as he continues as a service provider. After this grant, he holds 368,436 shares of Class A Common Stock directly.
Popovits Kimberly J reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Kimberly J. Popovits received an equity award in the form of restricted stock units. She was granted 8,829 RSUs, each representing one share of Class A Common Stock at no cash cost, bringing her direct holdings to 37,445 shares. One quarter of the RSUs will vest on each quarterly anniversary starting from May 21, 2026, as long as she continues as a service provider on those dates.
MATEO ALAN reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. director Alan Mateo reported an equity compensation grant in the form of 8,829 restricted stock units (RSUs) for Class A Common Stock. Each RSU represents one share upon vesting. The award vests in four equal quarterly installments beginning on May 21, 2026, contingent on continued service.
Following this grant, Mateo directly holds 85,877 shares of Class A Common Stock, reflecting his updated equity stake in the company.
Kosaraju Sridhar reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics director Sridhar Kosaraju reported a stock-based compensation award. He received a grant of 8,829 shares of Class A Common Stock as restricted stock units (RSUs) at no cash cost. After this grant, he holds 65,278 shares directly.
The RSUs vest in four equal installments on each quarterly anniversary starting on May 21, 2026, as long as he continues as a service provider through each vesting date. The filing also shows 3,000 Class A shares held indirectly through the Kosaraju Family Trust, where he serves as trustee.
10x Genomics, Inc. reported the results of its 2026 annual meeting of stockholders held via live webcast on June 4, 2026. Stockholders representing 198,815,518 votes, or approximately 90.5% of the 219,700,782 eligible votes, were present in person or by proxy, constituting a quorum.
Three Class I directors were elected to three-year terms expiring at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.